Zacks Investment Research downgraded shares of Cooper Companies (NYSE:COO) from a buy rating to a hold rating in a research report report published on Monday.

According to Zacks, “Year-to-date Cooper Companies had an impressive run on the bourse. The company has always witnessed impressive results at CooperSurgical business segment. The CooperVision segment also delivered strong sales. The segment continues to gain from the company’s silicone hydrogel lenses led by solid prospects in the MyDay, Clariti and Biofinity platforms. The company provided strong guidance for fiscal 2018. Notably, Cooper Companies has signed an asset-purchase agreement to acquire the flagship contraception platform of Israel-based Teva Pharmaceutical Industries — PARAGARD Intrauterine Device. On the flipside, intense competition in the contact lens space will continue to increase pricing pressure for the company. Added to this, escalating debt levels and foreign exchange vulnerability are likely to mar the company’s bottom line.”

Several other equities analysts have also commented on COO. Robert W. Baird set a $273.00 price target on shares of Cooper Companies and gave the company a buy rating in a research note on Monday, October 16th. Stephens reiterated an equal weight rating and issued a $250.00 price target (up from $235.00) on shares of Cooper Companies in a research note on Tuesday, September 12th. JPMorgan Chase & Co. reiterated a hold rating and issued a $235.00 price target on shares of Cooper Companies in a research note on Tuesday, September 12th. Raymond James Financial reiterated a buy rating and issued a $265.00 price target on shares of Cooper Companies in a research note on Monday, December 4th. Finally, BMO Capital Markets reiterated a buy rating and issued a $272.00 price target on shares of Cooper Companies in a research note on Friday, October 13th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $259.70.

Shares of Cooper Companies (NYSE COO) traded up $2.20 during trading hours on Monday, reaching $230.84. 352,605 shares of the company traded hands, compared to its average volume of 529,756. The firm has a market capitalization of $11,280.00, a PE ratio of 30.70, a price-to-earnings-growth ratio of 1.86 and a beta of 0.54. Cooper Companies has a 52-week low of $177.06 and a 52-week high of $256.39. The company has a current ratio of 2.41, a quick ratio of 1.26 and a debt-to-equity ratio of 0.36.

Cooper Companies (NYSE:COO) last announced its quarterly earnings results on Thursday, December 7th. The medical device company reported $2.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.64 by $0.01. The company had revenue of $561.50 million for the quarter, compared to analyst estimates of $558.86 million. Cooper Companies had a net margin of 17.43% and a return on equity of 16.02%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.28 earnings per share. research analysts predict that Cooper Companies will post 11.51 EPS for the current fiscal year.

The firm also recently announced a semiannual dividend, which will be paid on Friday, February 9th. Stockholders of record on Tuesday, January 23rd will be given a dividend of $0.03 per share. The ex-dividend date is Monday, January 22nd. This represents a dividend yield of 0.03%. Cooper Companies’s dividend payout ratio (DPR) is presently 0.80%.

In other news, Director Allan E. Rubenstein sold 500 shares of the firm’s stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $222.00, for a total transaction of $111,000.00. Following the transaction, the director now directly owns 6,590 shares in the company, valued at $1,462,980. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Stanley Md Zinberg sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $224.66, for a total transaction of $1,123,300.00. Following the transaction, the director now owns 6,090 shares in the company, valued at $1,368,179.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,935 shares of company stock worth $10,813,768. Insiders own 1.60% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Advisory Services Network LLC grew its position in shares of Cooper Companies by 30.6% during the second quarter. Advisory Services Network LLC now owns 457 shares of the medical device company’s stock worth $109,000 after acquiring an additional 107 shares during the last quarter. Motley Fool Asset Management LLC grew its position in shares of Cooper Companies by 2.8% during the third quarter. Motley Fool Asset Management LLC now owns 36,400 shares of the medical device company’s stock worth $8,631,000 after acquiring an additional 1,000 shares during the last quarter. Korea Investment CORP grew its position in shares of Cooper Companies by 23.9% during the third quarter. Korea Investment CORP now owns 17,109 shares of the medical device company’s stock worth $4,057,000 after acquiring an additional 3,300 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Cooper Companies by 11.4% during the third quarter. California Public Employees Retirement System now owns 120,582 shares of the medical device company’s stock worth $28,591,000 after acquiring an additional 12,382 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Cooper Companies by 0.9% during the second quarter. Dimensional Fund Advisors LP now owns 185,979 shares of the medical device company’s stock worth $44,525,000 after acquiring an additional 1,713 shares during the last quarter. Institutional investors and hedge funds own 96.73% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cooper Companies (COO) Rating Lowered to Hold at Zacks Investment Research” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/12/cooper-companies-coo-rating-lowered-to-hold-at-zacks-investment-research.html.

About Cooper Companies

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Get a free copy of the Zacks research report on Cooper Companies (COO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.